PRINCETON, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood ...

CytoSorb is the only approved therapy to remove ticagrelor in the European Union, and is intended to address a major unmet medical need of potentially life-threatening postoperative bleeding in ...

Add’l Clinical Evidence Indicates CytoSorb Associated w/ Improved Outcomes in Sepsis, Cardiac Surgery CytoSorbents (CTSO) recently announced the publication of two unrelated studies (one in sepsis, ...

After a long approval process, Monmouth Junction N.J.-based Cytosorbents Corp. received clearance to bring its Cytosorb blood purification technology to treat cytokine storm and deadly inflammation in ...

MONMOUTH JUNCTION, N.J., May 25, 2021 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb(R) blood purification technology to treat deadly ...

Please provide your email address to receive an email when new articles are posted on . CytoSorbents received European Union regulatory approval to expand the use of CytoSorb to reduce elevated ...

Many hospitals use the adsorber to purify the blood of seriously ill patients in order to trap inflammatory substances and prevent the life-threatening cytokine storm. MHH researchers have now found ...

NICE is committed to promoting equality of opportunity, eliminating unlawful discrimination and fostering good relations between people with particular protected characteristics and others. CytoSorb ...

In the first human retrospective study, CytoSorb and ex vivo lung perfusion prior to lung transplant increased in-hospital and one-year survival This same “enhanced lung rest” concept has carried over ...

MONMOUTH JUNCTION, N.J., Jan. 29, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader specializing in blood purification, announces that CytoSorb® is now ...

Organ transplantation is the gold standard treatment for end-stage organ failure. However, suitable donor organs are scarce and many patients often die waiting for an organ to become available.